B. Riley initiates coverage of Alpha Cognition with a Buy rating, citing potential in its oral Alzheimer’s therapy Zunveyl.
Shares of Alpha Cognition (ACOG) rose after B. Riley Securities initiated coverage with a Buy rating and a $21 price target. The firm highlighted the biotech’s oral Alzheimer’s treatment, Zunveyl, as a key driver for the optimistic outlook.
The initiation follows growing interest in Alzheimer’s therapies, though prior market reactions to similar drug developments have been mixed. Analysts had not widely covered ACOG before this rating, limiting direct comparisons to earlier performance.
The stock’s upward movement reflects investor response to the new coverage and target, though broader market conditions may influence further gains.